Laborie has struck a $239 million deal to buy Cogentix Medical. The takeover will give Laborie control of devices for the treatment of overactive bladder (OAB) and stress urinary incontinence (SUI).
Cogentix has built its business around a urology portfolio spearheaded by a neuromodulation device to treat overactive bladder and a soft-tissue bulking agent for managing stress urinary incontinence. Double-digit urology growth last year took the unit’s annual sales up toward the $50 million mark, pushing Cogentix’s overall revenues beyond $56 million.
The revenue figure is well short of the three-year goal Cogentix set when it was created through the 2015 merger of Uroplasty and Vision-Sciences. But equally it is up on the period shortly after the merger when a combination of debt and competition from the far-larger Medtronic threatened Cogentix’s prospects. A subsequent investment by Accelmed and conversion of the debt into equity enabled Cogentix to invest in its sales team and fight back.
Accelmed has been rewarded with a big return on the stock it picked up when Cogentix was at a low ebb. The payday follows Laborie’s identification of Cogentix’s Urgent PC Neuromodulation System and Macroplastique as a good fit for its urology business.
“The acquisition of Cogentix advances our strategy to invest in leading technologies that provide product and channel scale to Laborie’s existing urology strategic business unit diagnostic and therapeutic portfolio, particularly in the areas of OAB and SUI,” Laborie CEO Michael Frazzette said in a statement.
When the deal closes, Cogentix’s products will slot into a business unit that already sells ultrasound bladder scanners, pelvic floor diagnostics and other urology devices. Laborie is paying a 14% premium over Cogentix’s closing price the day before the deal was disclosed to acquire the device manufacturer.
By Nick Paul Taylor
Source: Fierce Biotech
A monkeypox outbreak is emerging in the U.S. and Europe, and at least one country is amping up countermeasure preparedness. Bavarian Nordic has secured a contract with an unnamed European country to supply its smallpox vaccine, called Imvanex in Europe, in response to the emergence of monkeypox cases, the Danish company said Thursday.
Moderna’s recent chief financial officer debacle—in which Jorge Gomez departed on his second day on the job—raised questions about the company’s hiring process given its rush to global biopharma prominence. The most obvious one: How was it possible for Gomez to be hired when he was under investigation by his previous employer, Dentsply Sirona of Charlotte, N.C.
Merck & Co. is plucking a cancer project from the branch of Chinese-based Kelun Pharmaceutical for up to $1.4 billion, but details from the New Jersey-based Big Pharma have been hard to come by. The deal, first disclosed Monday on the Shenzhen stock exchange, has Merck handing over $47 million in upfront cash in exchange for ex-China rights to a “macromolecular tumor project.”
